Bone Biologics Corp (BBLG) stock
Close on Nov 18, 2026Market cap $986.22KP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Sep 30, 2026
Valuation
- Market cap
- $986.22K
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 0.17
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- -$2.84M
- EPS, diluted
- -$2.65
- Book value per share
- $1.59
- Diluted shares
- 4M
Trading
- Previous close
- $0.31
- Open
- $0.32
- Day's range
- $0.28 – $0.32
- Volume
- 39,418
- Average volume (20 days)
- 459,838
- 52-week range
- $0.27 – $2.39
- RSI (14 days)
- 33.7
- Volatility (1 year)
- 70.1%
- Relative volume
- 0.11×
Market cap history
Month-end market cap since 2018, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 18, 2026. The S&P 500 is measured by the SPY fund.
| Period | BBLG | S&P 500 | Difference | BBLG per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -26.3% | -4.3% | −22.0 pts | ||
| 3 months | -54.8% | -4.6% | −50.1 pts | ||
| Year to date | -79.9% | +7.9% | −87.8 pts | ||
| 1 year | -82.1% | +11.8% | −94.0 pts | ||
| 3 years | -99.0% | +68.0% | −167.0 pts | -78.5% | +18.9% |
| 5 years | -100.0% | +66.2% | −166.2 pts | -85.8% | +10.7% |
Fifteen years at a glance
Fiscal years 2010 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Bone Biologics filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- News
- Update
- Update
- News
- News
About Bone Biologics
Orthopedic, Prosthetic & Surgical Appliances & Supplies
Bone Biologics Corporation is a clinical-stage medical device company focused on bone regeneration in spinal fusion surgery. Its core technology platform utilizes NELL-1, a proprietary recombinant human protein growth factor designed to regulate skeletal tissue formation and stem cell differentiation. The company's lead product candidate is NB1, a combination medical device that incorporates the NELL-1 recombinant protein with demineralized bone matrix (DBM). The product is designed to promote targeted bone growth during spinal fusion procedures, initially targeting adult patients with degenerative disc disease undergoing transforaminal lumbar interbody fusion. Beyond spinal applications, the company holds rights to develop the platform for osteoporosis and trauma treatments.
Company profile, executives and historyBone Biologics stock: common questions
What is Bone Biologics's stock price?
BBLG closed at $0.29 on Nov 18, 2026, down 5.92% on the day. Over the past 52 weeks it traded between $0.27 and $2.39.
What is Bone Biologics's market cap?
Bone Biologics was worth $986.22K at the close on Nov 18, 2026: the share price times the diluted shares outstanding.
What is BBLG's P/E ratio?
Bone Biologics lost money over fiscal 2025 (diluted EPS -$2.65), so it has no meaningful P/E ratio.
Does Bone Biologics pay a dividend?
No. Bone Biologics has not paid a cash dividend over the last twelve months.
How has BBLG stock performed over the past year?
Including dividends, BBLG returned -82.1% over the past year, against +11.8% for the S&P 500.
How many BBLG shares are sold short?
0M shares were sold short at the latest FINRA report, 0.52% of the float, or 1.0 days of average trading volume.
Who are Bone Biologics's competitors?
Companies most similar to Bone Biologics by business, industry and size include SMTI, RGNT, OPHI, OFIX, LFWD.
See a number that looks wrong?